GSK Ris-Rez SCLC Data: Phase III Trial Cuts Risk of Death by 54% Versus Topotecan
GSK’s B7-H3-targeted ADC Ris-Rez cut the risk of death by 54% versus topotecan in the Phase III ARTEMIS-008 trial in relapsed small cell lung cancer in China, with a median overall survival of 18.5 months and fewer severe side effects than chemotherapy.
